Marc M Perreault
Overview
Explore the profile of Marc M Perreault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saavedra-Mitjans M, David P, Arbour C, Perreault M, Roux M, Frenette A, et al.
Brain Inj
. 2025 Feb;
:1-12.
PMID: 39895622
Introduction & Objectives: Agitation is a common complication after an acute TBI in ICU patients. Professionals have a range of strategies to address agitation. Yet the absence of evidence-based guidelines...
2.
White G, Adessky N, Chen F, Regazzoni A, Tourian L, Chagnon M, et al.
Int J Clin Pharm
. 2023 Dec;
46(1):177-185.
PMID: 38071694
Background: Agitation is a common clinical problem encountered in the intensive care unit (ICU). Treatment options are based on clinical experience and sparse quality literature. Aim: The aim of this...
3.
Bolesta S, Burry L, Perreault M, Gelinas C, Smith K, Eadie R, et al.
Crit Care Med
. 2023 Jun;
51(11):1502-1514.
PMID: 37283558
Objectives: Iatrogenic withdrawal syndrome (IWS) associated with opioid and sedative use for medical purposes has a reported high prevalence and associated morbidity. This study aimed to determine the prevalence, utilization,...
4.
Mahmoud S, Hefny F, Panos N, Delucilla L, Ngan Z, Perreault M, et al.
Pharmacotherapy
. 2023 Mar;
43(4):279-290.
PMID: 36880540
Background: Nimodipine improves outcomes following aneurysmal subarachnoid hemorrhage (aSAH) and current guidelines suggest that patients with aSAH receive nimodipine for 21 days. Patients with no difficulty swallowing will swallow the...
5.
Bing E, Archambault K, Sananikone A, Nguyen K, Fang Y, Jabamikos C, et al.
Int J Clin Pharm
. 2022 Jul;
44(6):1277-1286.
PMID: 35834093
Background: Augmented renal clearance is increasingly recognized in critically ill patients. This condition may lead to suboptimal dosing of renally excreted medications. Aim: Our primary objective was to identify demographic...
6.
Jabamikos C, Fang Y, Nguyen K, Sananikone A, Archambault K, Bing E, et al.
J Clin Pharm Ther
. 2022 May;
47(10):1517-1524.
PMID: 35633117
What Is Known And Objective: Augmented renal clearance is prevalent in trauma patients and leads to subtherapeutic levels of renally eliminated medications with potentially unfavourable clinical outcomes. The Augmented Renal...
7.
8.
9.
Sneyers B, Duceppe M, Frenette A, Burry L, Rico P, Lavoie A, et al.
Drugs
. 2020 Jun;
80(12):1211-1233.
PMID: 32592134
Background: Critically ill patients are at high risk of iatrogenic withdrawal syndrome (IWS), due to exposure to high doses or prolonged periods of opioids and benzodiazepines. Purpose: To examine pharmacological...
10.
Perreault M, Williamson D, Capilnean A
Am J Crit Care
. 2020 May;
29(3):168-169.
PMID: 32355979
No abstract available.